Magnesium sulphate vs placebo (outcomes: Major neurodevelopmental disability at childhood
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Magnesium sulphate vs placebo (outcomes Major neurodevelopmental disability (school age)** · women at risk of preterm birth (< 34 weeks' gestation) It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty). Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane Headline outcomes only | RR 0.92 [0.53, 1.62] | 2 studies · 940 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.